Korro Bio Inc (KRRO)

Currency in USD
15.700
-0.220(-1.38%)
Closed·
After Hours
15.710+0.010(+0.06%)
·
KRRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KRRO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.05015.780
52 wk Range
10.29098.000
Key Statistics
Prev. Close
15.92
Open
15.78
Day's Range
15.05-15.78
52 wk Range
10.29-98
Volume
108.03K
Average Volume (3m)
137.73K
1-Year Change
-55.8%
Book Value / Share
14.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KRRO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
100.829
Upside
+542.22%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Korro Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Korro Bio Inc Company Profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Korro Bio Inc SWOT Analysis


RNA Editing Pionee
Korro Bio leads in RNA editing therapies, with KRRO-110 for Alpha-1 Antitrypsin Deficiency advancing to Phase 1/2 trials, promising a potential breakthrough in genetic disorder treatment
Market Opportunity
Explore the vast potential in AATD treatment, with 200,000 patients in the US and EU, and Korro Bio's strategic positioning to capture a significant market share
Financial Health
Delve into Korro Bio's solid financial footing, with a cash runway extending to 2026 and a healthy current ratio of 8.79x, supporting crucial R&D efforts
Analyst Optimism
Discover why analysts set price targets ranging from $105 to $120, reflecting confidence in Korro Bio's innovative platform and potential for multi-indication applications
Read full SWOT analysis

Compare KRRO to Peers and Sector

Metrics to compare
KRRO
Peers
Sector
Relationship
P/E Ratio
−1.7x−1.4x−0.5x
PEG Ratio
−0.03−0.030.00
Price/Book
1.1x1.6x2.6x
Price / LTM Sales
30.6x10.0x3.3x
Upside (Analyst Target)
-309.8%43.5%
Fair Value Upside
Unlock32.8%6.9%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 100.829
(+542.22% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-2.49 / -2.66
Revenue / Forecast
2.55M / --
EPS Revisions
Last 90 days

KRRO Income Statement

People Also Watch

16.26
SRPT
-2.93%
83.12
OKLO
-1.16%
9.680
UUUU
-2.42%

FAQ

What Stock Exchange Does Korro Bio Trade On?

Korro Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Korro Bio?

The stock symbol for Korro Bio is "KRRO."

What Is the Korro Bio Market Cap?

As of today, Korro Bio market cap is 147.52M.

What Is Korro Bio's Earnings Per Share (TTM)?

The Korro Bio EPS (TTM) is -9.44.

From a Technical Analysis Perspective, Is KRRO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Korro Bio Stock Split?

Korro Bio has split 1 times.

How Many Employees Does Korro Bio Have?

Korro Bio has 112 employees.

What is the current trading status of Korro Bio (KRRO)?

As of 07 Aug 2025, Korro Bio (KRRO) is trading at a price of 15.70, with a previous close of 15.92. The stock has fluctuated within a day range of 15.05 to 15.78, while its 52-week range spans from 10.29 to 98.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.